Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

Factors that aid survival of prostate cancer cells in the presence of the various categories of cytotoxic cytokines present in tumors in vivo are largely unknown. Osteoprotegerin (OPG) is a decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that inhibits TRAIL-induced...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Holen, I, Croucher, P, Hamdy, F, Eaton, C
التنسيق:	Journal article
اللغة:	English
منشور في:	2002

مواد مشابهة

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
حسب: Eaton, C, وآخرون
منشور في: (2004)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
حسب: Eaton, C, وآخرون
منشور في: (2004)

OPG is a survival factor for breast- and prostate cancer cells in vitro
حسب: Holen, I, وآخرون
منشور في: (2002)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
حسب: Holen, I, وآخرون
منشور في: (2002)

Role of osteoprotegerin (OPG) in cancer.
حسب: Holen, I, وآخرون
منشور في: (2006)

The role of osteoprotegerin in breast and prostate cancer
حسب: Holen, I, وآخرون
منشور في: (2002)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
حسب: Holen Ingunn, وآخرون
منشور في: (2009-07-01)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
حسب: Shipman, C, وآخرون
منشور في: (2002)

Role of Osteoprotegerin (OPG) in Bone Marrow Adipogenesis
حسب: Lili Zhang, وآخرون
منشور في: (2016-11-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
حسب: Shipman, C, وآخرون
منشور في: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
حسب: Shipman, C, وآخرون
منشور في: (2000)

Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome
حسب: Gamal B Mohamed, وآخرون
منشور في: (2011-01-01)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
حسب: Waterman, E, وآخرون
منشور في: (2007)

Polymorphisms within the osteoprotegerin (OPG) gene are associated with both serum OPG levels and bone mineral density.
حسب: Miles, L, وآخرون
منشور في: (2004)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
حسب: Croucher, P, وآخرون
منشور في: (2000)

Endogenous osteoprotegerin (OPG) represses ERα and promotes stemness and chemoresistance in breast cancer cells
حسب: Noura N. Alraouji, وآخرون
منشور في: (2024-08-01)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
حسب: Riham Eid, وآخرون
منشور في: (2023-06-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
حسب: Shipman, C, وآخرون
منشور في: (2003)

Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19
حسب: Siamak Kazemi-Sufi, وآخرون
منشور في: (2024-09-01)

Human bone marrow stromal cells protect prostate and breast cancer cells from TRAIL-induced apoptosis
حسب: Nyambo, R, وآخرون
منشور في: (2004)

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
حسب: Nyambo, R, وآخرون
منشور في: (2004)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
حسب: Chan Kai-Ming, وآخرون
منشور في: (2011-07-01)

Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease
حسب: Syed Muhammad Muneeb Akhtar, وآخرون
منشور في: (2024-07-01)

Osteoprotegerin and the development of myeloma bone disease
حسب: Croucher, P, وآخرون
منشور في: (2004)

Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts
حسب: Yao Jing, وآخرون
منشور في: (2011-03-01)

Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
حسب: Saba Tariq, وآخرون
منشور في: (2022-02-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
حسب: Yosra Azizpour, وآخرون
منشور في: (2020-01-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
حسب: Yosra Azizpour, وآخرون
منشور في: (2020-01-01)

The survival effect of prolactin on PC3 prostate cancer cells.
حسب: Ruffion, A, وآخرون
منشور في: (2003)

Involvement of FXR in the OPG/RANKL pathway of breast and prostate cancer cells
حسب: Lara Absil, وآخرون
منشور في: (2021-04-01)

Significant Inverse Correlation of Serum Levels of Osteoprotegerin (OPG) and Transferrin Saturation in Thalassemia Dependent Transfusion (TDT) Patients
حسب: Indra Wijaya, وآخرون
منشور في: (2024-01-01)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
حسب: Croucher, P, وآخرون
منشور في: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
حسب: Croucher, P, وآخرون
منشور في: (2001)

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis
حسب: Lane Denis, وآخرون
منشور في: (2012-11-01)

Determinant Factors and Added Value of Osteoprotegerin (OPG) to Detect Carotid Intima-Media Thickness (CIMT) in Type 2 Diabetes Mellitus Patient
حسب: Shirly Elisa Tedjasaputra, وآخرون
منشور في: (2018-06-01)

Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids
حسب: Salvador Atilano-Miguel, وآخرون
منشور في: (2022-01-01)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
حسب: Martin Widschwendter, وآخرون
منشور في: (2015-10-01)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells
حسب: Cross, N, وآخرون
منشور في: (2008)

Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells.
حسب: Cross, N, وآخرون
منشور في: (2008)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
حسب: Vanderkerken, K, وآخرون
منشور في: (2003)